Clarus Therapeutics Holdings, Inc. announced immediate reduction in workforce by approximately 40% of total headcount. These changes will include staff reductions at all levels, including field sales personnel, coupled with significant reductions in promotional and other operational spend, including in its planned research and development activities, expected to be completed in August 2022.